PMID- 31966484
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200126
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 10
IP  - 11
DP  - 2017
TI  - microRNA-802 is involved in palmitate-induced damage to pancreatic beta cells 
      through repression of sirtuin 6.
PG  - 11300-11307
AB  - Free fatty acid (FFA)-induced pancreatic beta-cell loss is implicated in the 
      pathogenesis of type 2 diabetes mellitus (T2DM). It has been documented that 
      circulating microRNA (miR)-802 levels are significantly greater in T2DM patients 
      than in healthy subjects. However, the role of miR-802 in FFA-induced damage to beta 
      cells is still unclear. In the present study, we measured the expression of 
      miR-802 in the INS-1 rat insulinoma cell line after palmitate treatment for 48 h. 
      Gain- and loss-of-function studies were conducted to determine the function of 
      miR-802 in palmitate-induced apoptosis and reactive oxygen species (ROS) 
      production. The target gene(s) of miR-802 was functionally characterized. 
      Compared to control cells, palmitate treatment caused a time- and 
      concentration-dependent induction of miR-802 in INS-1 cells. Knockdown of miR-802 
      significantly blocked palmitate-induced apoptosis and attenuated ROS formation. 
      Moreover, miR-802 downregulation prevented the reduction of prosurvival proteins 
      Mcl-1 and Bcl-xL by palmitate. In contrast, ectopic expression of miR-802 
      stimulated apoptosis and ROS generation in INS-1 cells. Sirtuin 6 (SIRT6) was 
      identified to be a direct target gene of miR-802. Overexpression of miR-802 
      suppressed the expression of SIRT6. Enforced expression of SIRT6 abolished the 
      induction of apoptosis and ROS production by miR-802. Taken together, miR-802 is 
      required for palmitate-induced damage to beta cells by targeting SIRT6 and 
      represents a potential therapeutic target for T2DM.
CI  - IJCEP Copyright (c) 2017.
FAU - Lin, Ning
AU  - Lin N
AD  - Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiao 
      Tong University Shanghai, China.
FAU - Niu, Yixin
AU  - Niu Y
AD  - Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiao 
      Tong University Shanghai, China.
FAU - Zhang, Weiwei
AU  - Zhang W
AD  - Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiao 
      Tong University Shanghai, China.
FAU - Li, Xiaoyong
AU  - Li X
AD  - Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiao 
      Tong University Shanghai, China.
FAU - Yang, Zhen
AU  - Yang Z
AD  - Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiao 
      Tong University Shanghai, China.
FAU - Su, Qing
AU  - Su Q
AD  - Department of Endocrinology, Xinhua Hospital, School of Medicine, Shanghai Jiao 
      Tong University Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20171101
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC6965834
OTO - NOTNLM
OT  - Diabetes
OT  - SIRT6
OT  - free fatty acid
OT  - miR-802
COIS- None.
EDAT- 2017/11/01 00:00
MHDA- 2017/11/01 00:01
PMCR- 2017/11/01
CRDT- 2020/01/23 06:00
PHST- 2017/08/12 00:00 [received]
PHST- 2017/10/30 00:00 [accepted]
PHST- 2020/01/23 06:00 [entrez]
PHST- 2017/11/01 00:00 [pubmed]
PHST- 2017/11/01 00:01 [medline]
PHST- 2017/11/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2017 Nov 1;10(11):11300-11307. eCollection 2017.